Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery

Wu, Xiao Yu

doi:10.1517/17425247.2016.1165662

Cited by 73 publications

(43 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polymer-lipid hybrid nanoparticles (PLN) is another example of nanocarrier platform with unique advantages of superior co-loading multiple drugs with different properties [157]. Ability of the precise loading combined drugs at specific ratios into PLN requires manipulation of the amount and types of lipids and polymers, the ratio of lipid and polymer, and initial drug ratio in the feed during PLN formulation design [157, 158].…”

Section: Technical Challenges and Limitationsmentioning

confidence: 99%

“…Ability of the precise loading combined drugs at specific ratios into PLN requires manipulation of the amount and types of lipids and polymers, the ratio of lipid and polymer, and initial drug ratio in the feed during PLN formulation design [157, 158]. The optimal formulation can be identified by mathematic modeling ( e.g.…”

Section: Technical Challenges and Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

Zhang

Wong

Xue

et al. 2016

Journal of Controlled Release

Self Cite

285

166

View full text Add to dashboard Cite

Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy.

show abstract

Section: Technical Challenges and Limitationsmentioning

confidence: 99%

Section: Technical Challenges and Limitationsmentioning

confidence: 99%

Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

Zhang

Wong

Xue

et al. 2016

Journal of Controlled Release

Self Cite

285

166

View full text Add to dashboard Cite

show abstract

“…Prior to making the PLN system, we carefully reviewed properties of unsaturated liquid lipids and identified two candidates of unsaturated fatty acids (FA), i.e., a mono‐unsaturated FA oleic acid (OA) and a poly‐unsaturated fatty acid DHA. Incorporation of low melting temperature FA (i.e., OA or DHA) into PLN could spatially create amorphous form within its solid lipid matrix, thus improving drug loading, colloidal stability and reducing initial burst drug release .…”

Section: Resultsmentioning

confidence: 99%

Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrug‐Resistant Cancer Cells

Zhang

et al. 2017

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a main cause of chemotherapy failure in cancer treatment. It is associated with complex cellular and molecular mechanisms including overexpression of drug efflux transporters, increased membrane rigidity, and impaired apoptosis. Numerous efforts have been made to overcome efflux transporter-mediated MDR using nanotechnology-based approaches. However, these approaches fail to surmount plasma membrane rigidity that attenuates drug penetration and nanoparticle endocytosis. Here, a "one-two punch" nanoparticle approach is proposed to coordinate intracellular biointeraction and bioreaction of a nanocarrier material docosahexaenoic acid (DHA) and an anticancer prodrug mitomycin C (MMC) to enhance mitochondrion-targeted toxicity. Incorporation of DHA in solid polymer-lipid nanoparticles first reduces the membrane rigidity in live cancer cells thereby increasing nanoparticle cellular uptake and MMC accumulation. Subsequent intracellular MMC bioreduction produces free radicals that in turn react with adjacent DHA inducing significantly elevated mitochondrial lipid peroxidation, leading to irreversible damage to mitochondria. Preferential tumor accumulation of the nanoparticles and the synergistic anticancer cytotoxicity remarkably inhibit tumor growth and prolonged host survival without any systemic toxicity in an orthotopic MDR breast tumor model. This work suggests that combinatorial use of biophysical and biochemical properties of nanocarrier materials with bioreactive prodrugs is a powerful approach to overcoming multifactorial MDR in cancer.

show abstract

“…Wu et al [34,35] examined the structure of the PLNs. The structure of PLNs contains a monolithic matrix PLN and a core–shell PLN.…”

Section: Structural Models Of the Drug Carriersmentioning

confidence: 99%

A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs

Cai

Huang³

et al. 2017

Nanomaterials

182

108

View full text Add to dashboard Cite

Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid–polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, have been employed in recent years. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core–shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. Hence, we have reviewed the current state of development for the NLCs’, PNPs’, and PLNs’ structures, preparation, and applications over the past five years, to provide the basis for further study on a controlled release drug delivery system.

show abstract

Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery

Cited by 73 publications

References 15 publications

Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrug‐Resistant Cancer Cells

A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs

Contact Info

Product

Resources

About